- 4-Week Delivery: World’s fastest custom mouse model development.
- TurboMice™ Tech: Proprietary high-efficiency gene-editing platform.
- Full Capabilities: Expert conditional knockouts, knock-ins, and humanized models.
- Validated Quality: Guaranteed high precision and model viability.
Cd19-iCre Mouse Model
| Strain Name | C57BL/6NMcl-Cd19 tm1(P2A-NLS-iCre)/MCL |
|---|---|
| Editing Type | Knockin |
| Gene Name | Cd19/B-lymphocyte antigen CD19 |
| Gene Synonyms | B4, CVID3 |
| Strain Background | C57BL/6NMcl |
| NCBI No. | Gene ID: 12478 / MGI: 88339 |
| Biosafety Level | SPF |

- Studies on B-cell development and maturation
- Studies on B-cell antigen receptor signaling
- Studies on B-cell activation and germinal center responses
- Studies on humoral immunity and vaccine responses
- Studies on B-cell immune tolerance and autoimmune diseases
- Studies on the mechanisms of B-cell lymphomas and leukemias
- B-cell lineage tracing and conditional genetic modification studies
This line was generated by inserting a P2A-NLS-iCre expression cassette at the end of the coding sequence of the mouse Cd19 gene, immediately before the stop codon. In this model, Cd19 and NLS-iCre are expressed from the same open reading frame; during translation, P2A mediates ribosome skipping, so the upstream CD19 and downstream NLS-iCre are produced as two independent protein products [1]. The NLS is a nuclear localization signal that drives iCre into the nucleus; iCre is a Cre recombinase codon-optimized for mammalian expression, which recognizes loxP sites and mediates site-specific DNA recombination [2]. This line is a constitutive Cre driver model and does not require tamoxifen induction.
Cd19 encodes CD19, a B-cell surface transmembrane glycoprotein that is an essential component of the B-cell co-receptor complex. It regulates the signaling threshold of the B-cell antigen receptor, B-cell development, and humoral immune responses [3]. Cd19 is expressed throughout B-cell development, and its endogenous regulatory elements have been used to drive Cre-mediated recombination in the B-cell lineage; this strategy has been validated in bone marrow pre-B cells and splenic B cells [4].
When Cd19-P2A-NLS-iCre mice are crossed with mice carrying floxed alleles, they enable conditional genetic modifications in Cd19-positive B cells and their descendant lineages. When crossed with Cre-dependent reporter mice, reporter activation allows cell labeling and lineage tracing. This model provides a genetic tool for studying gene function in B-cell development, activation, immune tolerance, antibody responses, and related diseases.
- Endogenous expression-driven: NLS-iCre expression is controlled by the endogenous Cd19 regulatory elements.
- Separated protein expression: P2A mediates cotranslational separation of CD19 and NLS-iCre.
- Nuclear localization design: The NLS promotes iCre import into the nucleus.
- No drug induction required: Constitutive recombination is activated together with Cd19 expression.
- Compatible genetic tools: Can be paired with floxed alleles or Cre reporter systems.
iCre is successfully expressed in Cd19-iCre mice, with minimal impact on endogenous Cd19 expression.
Relative expression of iCre and Cd19 in the liver and spleen of Cd19-iCre mice. Liver and spleen tissues were collected from mice, and relative expression was calculated using the 2^−ΔCt method with Gapdh as the internal reference. Blue bars represent iCre and orange bars represent Cd19; data are shown as mean ± SD. In both the liver and spleen of WT mice, the iCre signal was not detected (ND) and was not assigned a value of zero or included in numerical calculations. In the liver of Cd19-iCre mice, iCre expression reached approximately 4.79 × 10⁻⁴, with endogenous Cd19 at approximately 2.81 × 10⁻⁴ — in the same order of magnitude as WT liver (Cd19 ≈ 4.35 × 10⁻⁵), confirming that the P2A-NLS-iCre insertion did not substantially disrupt Cd19 expression. In the spleen, where B cells are abundant, expression was markedly higher: iCre reached approximately 0.436 and Cd19 approximately 0.539, closely matching the Cd19 level in WT spleen (approximately 1.063). The high spleen-to-liver expression ratio is consistent with the known B-cell–enriched distribution of Cd19, and the absence of iCre signal in WT tissues confirms the specificity of the knock-in.

FAQ
Game-changing benefits?
While competitors highlight germline efficiency gains, shorter timelines and enhanced 3Rs animal welfare benefits for their technologies, these are merely incremental improvements over traditional approaches. In sharp contrast, our proprietary technology delivers fully pure, homogeneous lineages—every single cell of the mice is derived exclusively from totipotent ES cells, with guaranteed 100% germline transmission efficiency. To experience these unparalleled benefits firsthand, enquire about your custom mouse model project with us or order embryos for in-house validation at your facility.
How much for a project assessment?
•Free initial design proposal with zero obligations.
•Request a free quote!
Who owns the mouse lP? Do l need a licence from Mingceler?
All model generation projects of Mingceler operate under a fee-for-service framework.
IP Ownership: All intellectual property rights related to custom mouse models, including derived organs, tissues, cells, and biological materials, are the sole and exclusive property of the Client.
Third-Party Transfer Permission: The Client may independently decide to retain, utilize, or commercialize their custom models project materials (e.g., targeting vectors, ES cells, mouse lines) without the need for prior consent from Mingceler.
Licensing Exemption: The Client has full autonomy over all uses of the custom models or their derivatives, including but not limited to commercialization, distribution to third parties, and publication involving model data. No written license from Mingceler is required for such uses.
